ReviewFrontiers in medicine2022
Novel imaging techniques for hydroxychloroquine retinopathy.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Progression of hydroxychloroquine-induced retinopathy after drug cessation.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Observational
- Progressive Retinal Toxicity Nine Years After Hydroxychloroquine Discontinuation: A Case Report.Cureus · 2025Article
- Effect of Cataracts on Hydroxychloroquine Retinopathy Screening.Diagnostics (Basel, Switzerland) · 2025Article
- Role of microperimetry to detect early visual function deficits in patients with hydroxychloroquine retinal toxicity-a review.Eye (London, England) · 2025Review
- Transscleral optical phase imaging of retinal pigment epithelium in a case of chloroquine maculopathy.American journal of ophthalmology case reports · 2025Article
- Subtle Presentations and Diagnostic Complexities of Hydroxychloroquine Retinopathy: A Case Series.Cureus · 2025Article
- Retromode Infrared Scanning Laser Ophthalmoscopy in Vogt-Koyanagi-Harada Disease.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy.Current ophthalmology reports · 2024Article
- New proposal for a multimodal imaging approach for the subclinical detection of hydroxychloroquine-induced retinal toxicity in patients with systemic lupus erythematosus.BMJ open ophthalmology · 2024Article
- Retro-Mode in NIDEK Mirante: A Comparative Analysis with Other Imaging Modalities for AMD and CSR.Diagnostics (Basel, Switzerland) · 2023Article
- Detection of Hydroxychloroquine Retinopathy via Hyperspectral and Deep Learning through Ophthalmoscope Images.Diagnostics (Basel, Switzerland) · 2023Article
- Review of Retinal Imaging Modalities for Hydroxychloroquine Retinopathy.Diagnostics (Basel, Switzerland) · 2023Review
- Causes and trends of late diagnosis in Korean patients with hydroxychloroquine retinopathy.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Hydroxychloroquine retinopathy is an increasingly recognized cause of iatrogenic, irreversible visual impairment due to the expanding use of hydroxychloroquine in combination with improvements in disease detection following advances in retinal imaging techniques. The prevalence of disease is estimated to be greater than 5% amongst individuals who have used the drug for 5 years or more. In addition to conventional imaging modalities, such as spectral-domain optical coherence tomography (OCT) and fundus autofluorescence (FAF), novel retinal imaging techniques such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.